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Gabra3Previous studies in our laboratory have shown that the neuron-speciﬁc speciﬁcity protein 4 (Sp4) transcriptionally
regulatesmany excitatory neurotransmitter receptor subunit genes, such as those forGluN1, GluN2A, andGluN2Bof
N-methyl-D-aspartate (NMDA) receptors and Gria2 of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors. It also regulates Atp1a1 and Atp1b1 subunit genes of Na+/K+-ATPase, a major energy-
consuming enzyme, as well as all 13 subunits of cytochrome c oxidase (COX), an important energy-generating
enzyme. Thus, there is a tight coupling between energy consumption, energy production, and excitatory neuronal
activity at the transcriptional level in neurons. The question is whether inhibitory neurotransmitter receptors are
also regulated by Sp4. In the present study, we tested our hypothesis that Sp4 regulates receptor subunit genes of
a major inhibitory neurotransmitter, GABA, speciﬁcally GABAA receptors. By means of multiple approaches, in-
cluding in silico analysis, electrophoretic mobility shift and supershift assays, real-time quantitative PCR, chromatin
immunoprecipitation, promoter mutational analysis, over-expression and shRNA of Sp4, functional assays, and
western blots, we found that Sp4 functionally regulates the transcription of Gabra1 (GABAA α1) and Gabra2
(GABAAα2), but notGabra3 (GABAAα3) subunit genes. The binding sites of Sp4 are conserved among rats, humans,
and mice. Thus, our results substantiate our hypothesis that Sp4 plays a key role in regulating the transcription of
GABAA receptor subunit genes. They also indicate that Sp4 is in a position to transcriptionally regulate the balance
between excitatory and inhibitory neurochemical expressions in neurons.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Neuronal activity and energymetabolism are tightly coupled process-
es [1]. Previously, we have shown that the neuron-speciﬁc speciﬁcity
protein 4 (Sp4) transcriptionally regulates many excitatory neurotrans-
mitter receptor subunit genes, such as Grin1 (GluN1), Grin2a (GluN2A),
and Grin2b (GluN2B) of N-methyl-D-aspartate (NMDA) receptors [2]
and Gria2 of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors [3]. It also regulates Atp1a1 and Atp1b1 subunit genes
of Na+/K+-ATPase, a major energy-consuming enzyme [4], as well as all
13 subunits of cytochrome c oxidase (COX), an important energy-
generating enzyme [5] in neurons. As neuronal activity involves both
excitation and inhibition, the question naturally arises as to how the in-
hibitory neurotransmitter receptors are transcriptionally regulated, and
if Sp4 plays a role in this regulation.ene name for GABAA receptor
y, Neurobiology and Anatomy,
d, Milwaukee, WI 53226, USA.Gamma-aminobutyric acid (GABA) is the major inhibitory neuro-
transmitter in the central nervous system [6,7] and the fast-acting
ionotropic type A receptors (GABAAR) are prevalent among neurons
[8,9]. Functional alterations of GABAA receptors are often associated
with a variety of disorders, such as epilepsy, anxiety, insomnia, and
schizophrenia [10], linking frequently to an excitation/inhibition imbal-
ance in speciﬁc populations of neurons [11–13]. Understanding the ge-
netic mechanism underlying the synaptic balance at the cellular and
molecular levels will lead to a better insight into normal and abnormal
functioning of neurons, and will lay a foundation for new therapeutic
tools for the prevention of a variety of neurological disorders. We have
uncovered the transcriptional regulation of a number of excitatory neu-
rotransmitter receptor genes [2,3,14–16]. Deciphering the transcrip-
tional regulation of different inhibitory GABAA receptor subunit genes
will be the next step towards such an understanding. The goal of the
present study was to determine if the three major GABAA receptor sub-
unit genes, Gabra1 (GABAA α1), Gabra2 (GABAA α2), and Gabra3
(GABAA α3) are transcriptionally regulated by the same transcription
factor, Sp4, as some of the key excitatory neurotransmitter receptor sub-
unit genes. Our hypothesis is that they are.
Bymeans ofmultiple approaches, including in silico analysis, electro-
phoreticmobility shift and supershift assays, real-timequantitative PCR,
chromatin immunoprecipitation, promoter mutational analysis, over-
Table 1
EMSA probes with putative Sp4 binding sites underlined.
Gene promoter EMSA sequence
Gabra1 F: 5′ TTTTGCATATAAAAAATGGGCGGATTGGTG 3′
R: 5′ TTTTCACCAATCCGCCCATTTTTTATATGC 3′
Gabra2 F: 5′ TTTTGGCCAGGATTGGGGTGGGGGATAAGGGG 3′
R: 5′ TTTTCCCCTTATCCCCCACCCCAATCCTGGCC 3′
Gabra3 F: 5′ TTTTCTACTTCATTGGGGTGGGGATCAG 3′
R: 5′ TTTTCTGATCCCCACCCCAATGAAGTAG′3′
GM3 synthase F: 5′ TTTTGCGCGACCCCGCCCCCGCCTA 3′
R: 5′ TTTTTAGGCGGGGGCGGGGTCGCGC 3′
Mutant Sp Gabra1 F: 5′ TTTTGCATATAAAAAATGGAAGGATTGGTG 3′
R: 5′ TTTTCACCAATCCTTCCATTTTTTATATGC 3′
Mutant Sp Gabra2 F: 5′ TTTTGGCCAGGATTGGGAAGGGGGATAAGGGG 3′
R: 5′ TTTTCCCCTTATCCCCCTTCCCAATCCTGGCC 3′
Table 2
Primers for ChIP analysis.
Gene promoter Sequence Amplicon length
Gabra1 F: 5′ GGAATGCTTGCAGCAGATTG 3′ 216 bp
R: 5′ GTAGTAATACGTCCCAGCGC 3′
Gabra2 F: 5′ GCAGGGTGTGGGCTCCACTC 3′ 290 bp
R: 5′ TAGCGATCGCAGGAGCCGG 3′
Gabra3 F: 5′ GACTGTTTTGCCTCCTTTGC 3′ 336 bp
R: 5′ CCTTCCATCTCTATGGGTGTGC 3′
GM3 synthase F: 5′ CACCTACTTCTCGGCTGGAG 3′ 198 bp
R: 5′ AATTCAGCCCCGGACAGT 3′
β-Actin F: 5′ GCTCTTTTCCAGCCTTCCTT 3′ 187 bp
R: 5′ CGGATGTCAACGTCACACTT 3′
2 B. Nair et al. / Biochimica et Biophysica Acta 1863 (2016) 1–9expression, shRNA, functional assays, and western blots, we found that
Sp4 functionally regulates the transcription of Gabra1 and Gabra2, but
not Gabra3 subunit genes in neurons.
2. Materials and methods
All experiments involving rats were approved by and conducted in
accordance with the Institutional Animal Care and Use Committee
(IACUC) of the Medical College of Wisconsin (Milwaukee, WI). All
efforts were made to minimize the number of animals used and their
suffering.
2.1. Primary neuronal cultures
Rat or mouse primary visual cortical neurons were cultured as
described previously [17]. In brief, neonatal one-to-two day old pups
were euthanized by decapitation. The brains were detached from the
skull, meninges were removed, and the visual cortex was dissected.
Pieces of the visual cortex were treated with trypsin and suspended
by pipetting. Neurons were then dissociated by trituration, and cells
were seeded in a six-well plate (35 mm; pre-coated with poly-L-lysine)
at a density of 1 × 106 cells/well. Cells were allowed to grow in
Neurobasal-A media containing L-glutamine and B27 supplement
(Life Technologies, Carlsbad, CA, USA) and maintained in a humidi-
ﬁed incubator with 5% CO2 at 37 °C. Cytosine arabinoside (Ara-C)
(Sigma, St. Louis, MO, USA) was added to the culture media to suppress
the division of glial/non-neuronal cells.
2.2. In silico analysis of GABAA receptor subunit promoters
UsingDNAStar Lasergene 8 Suite— Sequence Builder andGenequest
software, sequences surrounding 1 kb upstream and 1 kb downstream
of the transcription start points (TSPs) of mouse, rat, and human
GABAA receptor α1, α2, and α3 subunit genes (Gabra1, Gabra2, and
Gabra3) were derived from the genome database in GenBank and
were aligned using Megalign. Computer-assisted search for the typical
Sp bindingmotif (‘GGGCGG’), the atypical Sp bindingmotifs (‘GGGTGG’
and ‘CCCTCC’), or their complements, was conducted to uncover the pu-
tative Sp binding sites.
2.3. Preparation of nuclear extracts and electrophoretic mobility shift and
supershift assays
Nuclear extraction protocol was as reported previously [18]. In brief,
the frozen brain tissue was rinsed in the PBS buffer, spun and trans-
ferred to a Dounce tissue homogenizer. Buffer A was added at 2.5
times per g of the tissue weight with a minimum volume of 2 ml.
Five strokes of pestle were used to homogenize the tissue to a liquid
mass. After induction with NP-40 (0.5%), ﬁve additional strokes were
applied and the tissue was incubated for 10 min to lyse the cells with
the detergent. The homogenate was transferred equally into fresh tubes
and centrifuged at 13,000 rpm for 30 s. The supernatant containing the
cytoplasmic constituents was removed, and buffer C was added to the
nuclear pellet. Tubes were mixed thoroughly, placed on a rotary shaker
for 15 min, and centrifuged. The supernatant containing the protein
from the nuclear extract was removed carefully and transferred to a
fresh tube. The protein was measured, aliquoted, and stored at−80 °C
until use.
Electrophoretic mobility shift (EMSA) and supershift assays' proto-
cols were as described previously [3]. Based on the in silico analysis, ol-
igonucleotide probes with a putative Sp4 binding site on each promoter
were synthesized (Table 1), annealed, and labeled by a ﬁll-in reaction
with a Klenow fragment and [32P]dATP (50 μCi/200 ng; Perkin-Elmer,
Shelton, CT, USA). Each labeled probewas incubatedwith 2 g of calf thy-
mus DNA and 5 g of brain nuclear extract. For supershift experiments,
the reactions were incubated with 2 μg of Sp4 polyclonal antibodies(Sp4, V-20, SC-645, Santa Cruz Biotechnology [SCBT], Santa Cruz, CA,
USA) for 20 min at room temperature (RT). For competition, 100-fold
excess of unlabeled oligonucleotides were incubated with brain nuclear
extract before adding labeled or nonspeciﬁc oligonucleotides. Shift reac-
tionswere loaded onto 4% polyacrylamide gel and run at 200 V for 3 h in
0.25× TBE buffer. Gels were dried and exposed for 4–24 h at−80 °C.
Mouse GM3 synthase with a known Sp4 binding site was designed as
previously described [5] andwas used as a positive control. Sp4mutants
with mutated sequences were used as negative controls.
2.4. Chromatin immunoprecipitation assays
The protocol for in vivo chromatin immunoprecipitation (ChIP) was
as described previously [2] with a few modiﬁcations. Murine visual
cortical tissue was kept on ice at all times to avoid protein degradation.
Tissue was cut in a petri dish resting on a block of dry ice and then
chopped into tiny pieces, ﬁxed in 2% formaldehyde, and resuspended
in the swelling buffer (85 mM KCl, 5 mM PIPES, pH 8.0, 1% Nonidet P-
40, and protease inhibitors). The tissue was transferred to a Dounce ho-
mogenizer, homogenized and centrifuged to isolate the nuclei. The nu-
clei were resuspended and sonicated in SDS lysis buffer (1% SDS, 50mM
Tris–HCl, pH 8.1, 10 mM EDTA). Immunoprecipitation was performed
with anti-Sp4 polyclonal antibodies (2 μg). Two μg of anti-nerve growth
factor receptor (NGFR) antibodies (sc-6188, SCBT) or ‘no antibody’
blanks were used as negative controls. Based on our in silico analysis,
putative Sp binding sites were identiﬁed and semi-quantitative PCR
was performed by utilizing primers surrounding the Sp binding sites
(Table 2). GM3 synthase was the positive control. Neurotrophin 3 [19]
was also used (data not shown), and β-actin promoter (Actb) was the
negative control. PCR additives and cycling parameters were used to
improve the reproducibility and quality of ChIP. PCR products were
visualized in 2% agarose gels.
2.5. Luciferase reporter assay
Luciferase reporter constructs of the three GABAA receptor subunit
promoters (Gabra1, Gabra2, and Gabra3) were made by PCR cloning
Table 4
Sp4 shRNA sequences cloned into the pLKO.1 vector for silencing Sp4.
Gene Hairpin sequence
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mouse N2a cells [15] as template. Digestion with restriction enzymes
was performed, followed by ligation of the product directionally into a
pGL3 basic vector (Promega, Madison, WI). Sequences of primers used
for PCR cloning are provided in Table 3. Site-directedmutations of puta-
tive Sp factor binding sites in each promoter were generated using
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA,
USA). Primers used for mutagenesis are also listed in Table 3. All con-
structs were veriﬁed by sequencing.
Primary neuronswere cultured and plated into 24-well plates before
transfection. Each promoter construct was transfected into the primary
neurons using Neurofect (Genlantis, San Diego, CA). Each well re-
ceived 0.6 μg of reporter construct and 0.06 μg of pRL-TK Renilla lu-
ciferase vector [20]. Fireﬂy luciferase and Renilla luciferase activities
were measured sequentially using the Dual Luciferase Reporter
Assay System (Promega). The ﬁreﬂy luciferase activity was normal-
ized according to Renilla and expressed as relative luciferase units to
reﬂect the promoter activity.
2.6. Sp4 knockdown and KCl treatment
To knockdown Sp4 expression, a vector-based shRNA approach was
used, and two target sequences were chosen from the RNAi
Consortium's Public TRC Cloning Database at the Broad Institute
(Table 4) and each cloned into the pLKO.1 TRC cloning vector (Plasmid
10878; Addgene, Cambridge, MA, USA) as reported previously [5]. To
rule out the non-speciﬁc consequences of shRNA, the pLKO.1 non-
mammalian shRNA control vector SHC002 (Sigma), a scrambled nega-
tive control, was also used.
Transfection of primary neurons was carried out 4 days post-plating
with both Sp4 shRNA constructs (2 μg of each construct) or the pLKO.1
non-mammalian control (2 μg), using Neurofect transfection reagent
per 6-well plate according to themanufacturer's instructions (Genlantis).
TurboGFP (0.5 μg) vector was added to each well for transfection visuali-
zation and selection efﬁciency. Transfection efﬁciency was around 50–
60% before selection. Puromycin selection, however, effectively yielded
100% transfected cells. Transfection efﬁciency was observed using green
ﬂuorescence. Primary neurons transfected with shRNA against Sp4 were
further stimulated with KCl. A ﬁnal concentration of 20 mM KCl was
added to the culture medium for 5 h according to our published method
[2]. After this period, cells were harvested for RNA and protein isolation.
2.7. Sp4 over-expression and TTX treatment
Using GatewayMultisite Cloning kit (Invitrogen), human Sp4 clones
of cDNA (Open Biosystems Lafayette, CO, USA)were cloned into pcDNA
Dest40 vectors according to the manufacturer's instructions and as
described previously [21].
As mentioned above, the transfection protocol for over-expressing
Sp4 in primary cultures was similar to that described for shRNA. Either
2 μg of Sp4 over-expression vector, or 1.5 μg of the pcDNA3.1 emptyTable 3
Primers used for promoter cloning and mutagenesis analysis. Mutated Sp4 binding sites
are underlined with mutated nucleotides in bold.
Gene promoter Primer
Gabra1 F: 5′ CAGACGCGTTGCTTCCTAGCTTGCGTTCA 3′
R: 5′ CAGCTCGAGGTGCTCCTGCACTGGAGATT 3′




Gabra2 F: 5′ CAGGGTACCAAGGCGTGATTAGCCCCTTC 3′
R: 5′ CAGAAGCTTAAGACCAGGCAGCAAACGAA 3′
Mutant of Gabra2 F: 5′ GGCTTGGCCAGGATTGGGTTTTGGGATAAGGGGTCCCC 3′
R: 5′ GGGGACCCCTTATCCCAAAACCCAATCCTGGCCAAGCC 3′vector and 0.5 μg of turboGFP vector for green ﬂuorescence were used
for primary neuronal cultures. Transfected primary neurons were
blocked for 3 days with tetrodotoxin (TTX) at a ﬁnal concentration of
0.4 μMand starting on the day after transfection as previously described
[20]. Two to four days after transfection, neurons were harvested for
RNA and protein isolation.
2.8. Knockdown of Sp4 followed by over-expression of Sp4 with or without
KCl treatment
Two sets of experiments were performed. In the ﬁrst set, primary
neurons in culture were transfected with Sp4 shRNA as described in
Section 2.6 above for one day, then they were transfected with Sp4
over-expression vectors as described in Section 2.7 above for another
day. In the second set of experiments, primary neurons were also
transfected with Sp4 shRNA followed by transfection with Sp4 over-
expression vectors; however, in between the two procedures, they
were treated with KCl for 5 h as described in Section 2.6 above.
2.9. RNA isolation and cDNA synthesis
Cultured and transfected neurons were washed with PBS, followed
by the extraction of total RNA by the TRIzol (Life Technologies, Carlsbad,
CA, USA) method according to the manufacturer's instructions. Any re-
sidual genomic DNAwas digested with DNase I on total RNA, and cDNA
synthesis was carried out using an iScript cDNA synthesis kit (170–
8891, BioRad, Hercules, CA, USA).
2.10. Quantiﬁcation of gene expression by real-time PCR analysis
mRNA levels of various genes were determined in a BioRad iCycler
using IQ SYBR Green Supermix and/or Cepheid Smart Cycler Detection
system (Cepheid, Sunnyvale, CA, USA) following the manufacturer's
protocols. Primers for real-time are shown in Table 5. PCR runs as fol-
lows: hot start 2 min at 95 °C, denaturation 10 s at 95 °C, annealing
15 s according to the Tm of each primer, and extension 10 s at 72 °C
for 15–30 cycles.Melt curve analyses verify the formation of a single de-
sired PCR product.Mouse/rat compatible Actb (β-actin) andGapdhwereTable 5
Real-time qPCR primers.
Gene Primer
Gabra1 F: 5′ ACTGTCTTTGGAGTGACGACCGTT 3′
R: 5′ AATAAACCAGTCCATGGCCGTTGC 3′
Gabra2 F: 5′ TCAGTGCTCGAAATTCCCTTCCCA 3′
R: 5′ TACACTCTTTCCATCCCAAGCCCA 3′
Gabra3 F: 5′ AGGAAGCTCACACTTTGGTCCTGA 3′
R: 5′ TTGGCCAGTGGTTCCAGGTAGAAT 3′
Sp4 F: 5′ TTGCAGCAAGGCCAGCAGACC 3′
R: 5′ GCTTCTTCTTTCCTGGTTCACTGCT 3′
Actb F: 5′ GTGACGTTGACATCCGTAAAGA 3′
R: 5′ GCCGGACTCATCGTACTCC 3′
Gapdh F: 5′ AGGTCGGTGTGAACGGATTTG 3′
R: 5′ GGGGTCGTTGATGGCAACA 3′
4 B. Nair et al. / Biochimica et Biophysica Acta 1863 (2016) 1–9used as internal controls, and the 2−ΔΔCT method [22] was performed
for the relative amount of transcripts.
2.11. western blots
Control, Sp4 shRNA, and Sp4 over-expression protein samples were
harvested using the sample buffer (12.5 mM EDTA, 50 mM Tris–HCl
pH 6.8, 1% SDS, 10% glycerol). Equal protein amounts of each sample
were electrophoresed in SDS gels and transferred onto polyvinylidene
diﬂuoride membranes. Membranes were blocked with 5% non-fat dry
milk in TBS-T (150 mM NaCl, 50 mM Tris–HCl, pH 8.0, and 0.05%
Tween 20) at RT for 1 h, then incubatedwith primary antibodies against
Sp4 (1:1000; SCBT), GABAA α1, GABAA α2, or GABAA α3 (all at 1:1000;
all from Phosphosolutions, Aurora, CO, USA). The loading control was
β-actin (1:5000; Sigma) followed by an incubation with horseradish
peroxidase-conjugated secondary antibodies from Vector Laboratories
(Burlingame, CA, USA). ECL reagent was used to visualize protein posi-
tion and intensity on blots, which were exposed to autoradiographic
ﬁlms (RPI, Mount Prospect, IL, USA). Gel Doc system (BioRad) was
used to perform quantitative analyses of relative changes.
2.12. Statistical analysis
Data were analyzed using ANOVA. Signiﬁcance between two groups
was analyzed by Student's t test. P values of 0.05 or lesswere considered
signiﬁcant.
3. Results
3.1. In silico promoter analysis of GABAA receptor subunit genes
Proximal promoters of mouse and rat GABAA subunit genes Gabra1,
Gabra2, and Gabra3 with DNA sequence 1 kb 5′ upstream and 1 kb 3′
beyond TSP were analyzed using in silico analysis. The α1-subunitFig. 1. In vitro binding of Sp4 transcription factor to putative binding sites on GABAA receptor su
cleotides and are indicated by a “+” or a “−“sign depending onwhether they also containmou
Sp4 shift, supershift, and non-speciﬁc complexes are indicated by arrows. The positive contro
incubation with cortical nuclear extract (lane 1). Excess unlabeled competitor competed ou
(lane 3) corresponding to the presence of tandem Sp binding. Incubation of cortical nuclear e
respectively) that were competed out with the addition of excess cold probes (lanes 5 and 10
(lanes 6 and 11, respectively). The addition of excess unlabeled mutant Gabra1 and Gabra2 pro
and Gabra2 with Sp4 antibody without any nuclear extract was used as a positive control, to
bands (lanes 8 and 13). Labeled Gabra3 probes did not yield speciﬁc Sp4 shift (lane 14) or su
and Gabra2 probes with mutant Sp sites did not yield speciﬁc Sp4 shift or supershift bands (lagene is strongly expressed in all brain regions [23], and we found a
GC-rich promoter with many typical Sp binding motifs, the GC-box
(GGGCGG), as well as a TATA box upstream of the TSP. The Gabra2 pro-
moter also contained more than one typical binding motif, ‘CCCGCC’ as
well as atypical binding sites, whereas the Gabra3 promoter showed
atypical Sp binding sites, such as ‘GGGTGG’ or ‘CCCTCC’ and were con-
served only between mouse and rat, but not in humans.
3.2. In vitro Sp4 bound to GC-box region of GABAA subunits α1 and α2
Weperformed EMSA to determine if Sp4would bind to theGC boxes
of Gabra 1, 2, and 3 subunit promoters. Based on our previous ﬁnding
that GM3 synthase formed speciﬁc DNA/Sp4 shift and supershift com-
plexes with mouse visual cortical nuclear extract but was almost
faded or absentwithHeLa cell nuclear extract [3], we usedGM3 synthase
with murine visual cortical nuclear extract as our positive control. In-
deed, when incubated with mouse visual cortical tissue nuclear extract,
GM3 synthase formed speciﬁc DNA/Sp4 shift and supershift complexes
(Fig. 1, lanes 1 and 3 for Sp4 shift and supershift, respectively).
When murine visual cortical nuclear extract was incubated with
GABAA receptor subunit probes containing putative Sp4 sites, Gabra 1
and Gabra2 gave positive shift bands (Fig.1, lanes 4 and 9, respectively)
that were competed out with the addition of unlabeled competitors
(Fig. 1, lanes 5 and 10, respectively). A supershift band against Sp4
was present when Sp4 antibody was added to either Gabra1 or Gabra2
(Fig.1, lanes 6 and 11). The addition of unlabeled probes with mutated
Sp4 binding sites did not compete out the Sp4 shift bands (Fig. 1,
lanes 7 and 12). Labeled Gabra1 and Gabra2with Sp4 antibody without
any nuclear extract was also run to rule out antibody–oligo interaction,
and they did not show any shift or supershift bands (Fig. 1, lanes 8 and
13). Gabra3 did not give a positive shift (Fig. 1, lane 14) or a Sp4
supershift band (Fig.1, lane 16). Shift, competitor, and supershift reac-
tions with mutated Gabra1 and Gabra2 did not show any binding to
the Sp4 sites (Fig. 1, lanes 17–22).bunit promoters using EMSA and supershift assays. All lanes contain 32P-labeled oligonu-
se brain nuclear extract, excess unlabeled oligos, unlabeledmutant oligos, or Sp4 antibody.
l for Sp4 factor binding was GM3 synthase. Speciﬁc Sp4 shift bands were revealed upon
t the shift band (lane 2). The addition of Sp4 antibody yielded a strong supershift band
xtract with the Gabra1 and Gabra2 probes yielded speciﬁc Sp4 shift bands (lanes 4 and 9,
, respectively). The addition of Sp4 antibody yielded fainter but speciﬁc supershift bands
bes did not compete out the shift reaction (lanes 7 and 12, respectively). Labeled Gabra1
check for any antibody–oligo interaction, and they did not show any shift or supershift
pershift bands (lane 16), and cold competitor was also blank (lane 15). Labeled Gabra1
nes 17–19 and 20–22, respectively).
Fig. 3. Relative luciferase activity of the wild type Gabra1 and Gabra2 promoters (wt) and
the Gabra1 and Gabra2 promoters with a mutated Sp binding site (mut). Mutating the Sp
binding site onGabra1 andGabra2 resulted in a signiﬁcant decrease in luciferase activity as
compared to thewild type controls. N= 3 for each construct. ***= P b 0.001 as compared
to the wild type.
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To provide further corroboration of the physical association of Sp4
with its binding sites on the GABAA subunit promoters, we performed
a ChIP assay using mouse visual cortical tissue (Fig. 2). A 0.5% dilution
of input chromatin was used as a standard to indicate the efﬁciency of
the PCR. As Sp factors are known to regulate GM3 synthase [24], the pro-
moter of these genes were used as positive controls, whereas β-actin
exon 5 (Actb) served as a negative control.
When the sonicated nuclear lysates were immunoprecipitated with
Sp4 polyclonal antibodies and the resultant DNA was subjected to PCR
analysis, the anti-Sp4 antibody speciﬁcally co-precipitated the Gabra1
and Gabra2 promoter fragments, but failed to do so with the Gabra3
promoter. The appearance of a distinct bandwith Sp4 antibody veriﬁed
the in vivo interaction of GABAA receptor subunits Gabra1 and Gabra2
with Sp4. Nerve growth factor receptor (NGFR) antibody was used as
a control for the immunoprecipitation reaction and it did not yield any
PCR product. To rule out the possibility of a bead–DNA interaction, an
additional “no antibody” or blank control was used, which did not yield
any PCR product.
3.4. Effect of mutated Sp4 binding sites on the Gabra1 and Gabra2
promoters
Gabra1 and Gabra2 promoters that bound to Sp4 in vitro and in vivo
were each cloned into pGL3 basic luciferase vectors. Site-directedmuta-
tions of the putative Sp4 binding sites were constructed. Transfection of
control or mutated Sp promoter regions into cultured primary neurons
resulted in a signiﬁcant fall of 53% and 61% in the activity of Gabra1 and
Gabra2 promoters, respectively, containing the mutated Sp4 motif
(P b 0.001 for all, Fig. 3).
3.5. Knockdown of Sp4 decreased mRNA levels of GABAA receptors and the
effect of KCl depolarization in primary neurons
To provide further conﬁrmation to our ﬁndings, we employed
shRNA constructs targeted to Sp4 mRNA in cultured primary neurons.
β-Actin was used as an internal control. Sp4 protein showed a sig-
niﬁcant decline of 76% (P b 0.001). GABAA α1 and GABAA α2 were
decreased by 36.77% and 26.65%, respectively (P b 0.01, Fig. 4A,B),
whereas GABAA α3 did not show any remarkable change (Fig. 4A,B).Fig. 2. In vivo chromatin immunoprecipitation showing Sp4's interactions with GABAA
receptor subunit promoters inmouse visual cortical nuclear extract. Immunoprecipitation
was carried out with anti-Sp4 antibodies (Sp4 lane), anti-nerve growth factor receptor
p75 antibody (negative control, NGFR lane), or no antibody (negative control, blank
lane). 0.5% of input chromatin (input DNA lane) served as the control for PCR reaction.
The positive control for Sp4 binding was GM3 synthase, whereas β-actin was the negative
control. Sp4 interacted with Gabra1 and Gabra2, but not with Gabra3.With silencing, mRNA levels were also quantiﬁed, and β-actin and
Gapdh were used as internal PCR controls. For transfection controls,
neurons received scrambled shRNA, which failed to bind to any
known mRNA. Silencing of Sp4 resulted in a signiﬁcant decrease of
44% in Sp4 mRNA (P b 0.001), and signiﬁcant decreases of 56% and
54% in Gabra1 and Gabra2 mRNA levels, respectively (P b 0.01 for
both, Fig. 4C). On the other hand, mRNA levels of GABAA α3 did not
show any signiﬁcant change with silencing (Fig. 4C).
Primary cultured neurons (control and Sp4 transfected) were then
subjected to 20 mM KCl for 5 h. As shown in Fig. 4C, KCl depolarization
signiﬁcantly increased Sp4 itself, Gabra1, and Gabra2 transcript levels to
158%, 164%, and 152%, respectively (P b 0.05 for all). In the presence of
Sp4 shRNA, KCl could no longer increase transcripts of Sp4, Gabra1
and Gabra2 to levels of control-plus-KCl (P b 0.001, P b 0.01, and P b
0.001, respectively, when compared to control-plus-KCl). The values
of shRNA-plus-KCl were also not signiﬁcantly different from those of
shRNA alone (P = 0.218, P = 0.120, and P = 0.202, respectively,
when compared to shRNA alone). The transcript level of Gabra3 was
also signiﬁcantly increased with KCl treatment (P b 0.05), but was not
changed in the presence of Sp4 shRNA.
3.6. Sp4 silencing followed by over-expression rescued the effects of the
knockdown
Cultured primary neurons were transfected ﬁrst with Sp4 shRNA for
one day and then with Sp4 over-expression vectors for another day.
Over-expressionof Sp4was able to increase Sp4,Gabra1, andGabra2 tran-
script levels signiﬁcantly above those with Sp4 shRNA alone (P b 0.05 for
all), and these values were not signiﬁcantly different from those of con-
trols (Fig. 4C). This indicates that the shRNA-induced down-regulation
of transcripts was rescued by Sp4 over-expression. However, this combi-
nation had no effect on Gabra3 transcripts (Fig. 4C). Sp4-silenced primary
neurons treated with KCl for 5 h and then transfected with Sp4 over-
expression vectors showed increases in their mRNA levels of Sp4,
Gabra1, and Gabra2 that were signiﬁcantly above those treated with
shRNA and KCl but without over-expression (P b 0.001, P b 0.01, and
P b 0.01, respectively, when compared with shRNA-plus-KCl). Again,
Sp4 over-expression was able to counter the effect of shRNA and allowed
the neurons to be activated by KCl. Thus, the values of transcripts for Sp4,
Gabra1, andGabra2were not signiﬁcantly different between shRNA-plus-
KCl-plus-over-expression and control-plus-KCl. Again, this combination
had no effect on Gabra3 (Fig. 4C).
3.7. Over-expressing Sp4 increasedmRNA levels of GABAA receptors and the
effect of TTX blockade in primary neurons
To determine the effect of over-expressing Sp4 on transcript levels of
GABAA receptor subunits Gabra1 and Gabra2, Sp4 over-expression
Fig. 4. Effect of silencing Sp4, depolarizing stimulation, and Sp4 over-expressing. (A–B) western blots revealed a down-regulation of Sp4, GABAA α1, and GABAA α2, but not GABAA α3
protein levels in Sp4 shRNA-transfected primary neurons. β-Actin served as a loading control (N = 3). Using scrambled vector transfection as a control, primary neurons exposed to
KCl up-regulated their mRNA levels for Sp4, Gabra1, Gabra2, and Gabra3 (* P b 0.05 when compared with controls; N = 3). When transfected with Sp4 shRNA, transcript levels of Sp4,
Gabra1, and Gabra2 were signiﬁcantly down-regulated, but not that of Gabra3 (* P b 0.05; ** P b 0.01; X = non-signiﬁcant when compared to controls; N = 3). In the presence of Sp4
shRNA, KCl was no longer able to up-regulate mRNA levels of Sp4, Gabra1, and Gabra2 to that of control + KCl, though it was still able to do so for Gaba3 (## P b 0.01; ### P b 0.001;
X = non-signiﬁcant when compared to KCl alone). Transfection of neurons with Sp4 shRNA followed by Sp4 over-expression rescued their Sp4, Gabra1, and Gabra2 transcripts from
being down-regulated by Sp4 shRNA, but this treatment had no effect on Gaba3 (+P b 0.05; X = non-signiﬁcant when compared to shRNA alone; N = 3). Neurons transfected with
Sp4 shRNA followedby Sp4 over-expression aswell as KCl treatment showed a level of Sp4,Gabra1, andGabra2 transcripts thatwas signiﬁcantly higher than that of shRNA+KCl, although
it had no effect on that of Gabra3 (♦♦= P b 0.01; ♦♦♦= P b 0.001; X= non-signiﬁcant when compared to shRNA+ KCl; N= 3). All four transcript levels were not signiﬁcantly different
from those of control + KCl.
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used as the internal control. Sp4 over-expression increased the protein
levels of Sp4 to 196% (P b 0.001, Fig. 5A,B), and those of GABAA α1
and GABAA α2 to 182% and 144%, respectively (P b 0.001 for both,
Fig. 5A,B). Likewise, mRNA levels showed a similar pattern of change.
Over-expressing Sp4 signiﬁcantly increased the mRNA levels of Sp4 to
369%, and those of Gabra1 and Gabra2 to 210% and 293%, respectively
(P b 0.001 for all, Fig. 5C). On the other hand, neither GABAAα3 protein
nor Gabra3 mRNA exhibited any signiﬁcant change with Sp4 over-
expression (Fig. 5A–C).
To determine if Sp4 over-expression could rescue GABAA transcript
levels suppressed by TTX-induced impulse blockade, primary cultured
neurons (controls and Sp4 transfected) were subjected to 0.4 μM TTX
treatments for 3 days. Control neurons transfected with empty vectors
that were exposed to TTX showed a signiﬁcant decrease of 60%, 63%,
and 62% in transcript levels of Sp4, Gabra1, and Gabra2, respectively
(P b 0.01, P b 0.001, and P b 0.05, respectively; Fig. 5C). However,
neurons that were transfected with Sp4 over-expression vectors did
not exhibit any down-regulation of their transcript levels of Sp4,
Gabra1, and Gabra2 with TTX. Rather, these levels were 346%, 179%
and 309% respectively, as compared to controls (P b 0.001 for Sp4 andGabra2, and P b 0.01 for Gabra1 as compared to TTX alone; Fig. 5C).
Gabra3 transcript level decreased signiﬁcantly with TTX treatment
(P b 0.05) but was not rescued by Sp4 over-expression (Fig. 5C).
3.8. Homology
The functional Sp4 binding sites are conserved amongmice, rats, and
humans for Gabra1 and Gabra2 (Fig. 6).
4. Discussion
Thepresent study analyzed the proximal promoter regions of GABAA
receptor subunit genes Gabra1, Gabra2, and Gabra3 by means of multi-
ple molecular and biochemical approaches, including in silico analysis,
electrophoretic mobility shift and supershift assays, ChIP, RNA interfer-
ence, over-expression, functional assays, and western blots in rodent pri-
mary cortical neurons.We found thatGabra1 andGabra2, but notGabra3,
subunit genes are regulated by the neuron-speciﬁc transcription factor
Sp4. The typical Sp binding motifs on the Gabra1 and Gabra2 promoters
are conserved among mice, rats, and humans.
Fig. 5. Effect of over-expressing Sp4 on the transcript levels of GABAA receptor subunit genes. (A–B) Primary neurons transfectedwith Sp4 over-expression vectors revealed an up-regulation of
Sp4, GABAA α1, and GABAA α2 but not GABAA α3 protein levels using western blots (N = 3). (B) Sp4 over-expression also increased Sp4, Gabra1 and Gabra2 transcript levels but not that of
Gabra3 (N = 3). (C) Over-expression of Sp4 in primary neurons increased mRNA levels of Sp4, Gabra1, and Gabra2mRNA levels in primary neurons, but not of Gabra3. N= 3. * = P b 0.05,
** = P b 0.01, and *** = P b 0.001 when compared to controls. Transcript levels of Sp4 and all three GABAA receptor subunit genes were decreased with 3 days of 0.4 μM TTX treatment.
Sp4 over-expression rescued the TTX-mediated down-regulation of Sp4, Gabra1, and Gabra2 transcript levels, but not that of Gabra3. N = 3. * = P b 0.05, ** = P b 0.01, and *** = P b 0.001
when compared to controls. ## = P b 0.01, ###= P b 0.001 and X= non-signiﬁcant when compared to TTX treatment alone.
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that bind to GC-rich DNA motifs and regulate the expression of a large
number of genes implicated in various biological functions [25]. The
Sp binding site, also known as the GC box, contains an asymmetric
hexanucleotide core ‘GGGCGG’ sequence with high afﬁnity, or the GT
(‘GGGTGG’) or CT (‘CCCTCC’) boxes with signiﬁcantly lower afﬁnities,
and is recognized by members of the Sp/KLF family of transcriptionFig. 6. Aligned partial sequences of the Gabra1 and Gabra2 promoters frommice, rats, and
humans showed conserved Sp binding sites (boxed and underlined).factors with zinc ﬁnger motifs [25,26]. Increasing evidence indicates
that Sp4 is amply expressed in the brain, with high levels in neurons
and low levels in astrocytes [5,27,28]. Sp4 reportedly regulates develop-
mental cerebellar dendritic patterning, postnatal development of hippo-
campal dentate granule cells, postnatal hippocampal cell proliferation,
hippocampal long-term potentiation, and animal behaviors including
contextual and spatial memory, sensorimotor gating, and prepulse in-
hibition, some of which have been associated with psychiatric disorders
[29–31]. Although Sp–cismotif has been reported in the promoter regions
of Gabra1 and Gabra2 [32], it has not been characterized previously. The
present study provides experimental evidence frommultiple approaches
that Sp4 functionally regulates the expression of Gabra1 and Gabra2 in
neurons.
GABAA receptors are the dominant inhibitory neurotransmitter
receptors in the brain, and their kinetics is known to be faster than
that of GABAB by roughly ten-fold [33]. Binding of GABA to ionotropic
GABAA receptors opens the intrinsic ion channels, enabling the inﬂux
of chloride through the channels and subsequent hyperpolarization of
neurons [34]. At least 19 GABAA receptor subunit isoforms (α1–6,
β1–3, γ1–3, ρ1–3, π, θ, δ and ε) have been characterized in mammals
[35,36]. The most typical heteropentameric GABAA receptors contain
two α, two β, and one γ subunits [37,38].
Our current study indicates that Sp4 regulates the Gabra1 and
Gabra2 but not Gabra3 subunit genes of GABAA receptors. We have fo-
cused on these three subunits because they are developmentally
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provides the interface for binding GABA [46] and benzodiazepine [47].
GABAA α1 expression increases with age, reaching a stable level in
the adult [44,48] as well as in the aging brain [49]. In the immature cor-
tex, the kinetics of the ionotropic GABAA receptors is relatively slow
[45], but it accelerates three-fold during development until GABAA α1
dominates the receptor complex [50]. The GABAAα1 subunit is respon-
sible for sedative, amnestic, and anticonvulsant actions [51] and is also
known to drive ocular dominance plasticity in the visual cortex [52].
Theα1 subunit also has a high-afﬁnity for bindingGABA andbenzodiaz-
epine receptor ligands [53]. It is now clear that this important subunit is
transcriptionally regulated by Sp4 (the present study).
The distribution and expression of the GABAAα2 subunit are report-
edly strong in the superﬁcial layers of the neocortex and become abun-
dant and widespread within the whole cortex during development;
they then show a stable expression only in the superﬁcial layers during
adulthood and aging [49]. In the rat brain stem, this subunit is main-
tained at a steady level during the ﬁrst three postnatal weeks [42,43].
It is thought to mediate anxiolytic actions [51,54] and is involved in
modulating neuronal ﬁring [52]. The persistence of α2 into adulthood
underscores the importance of Sp4 in its regulation.
In contrast, theGABAAα3 subunit is abundantly expressed only dur-
ing the early postnatalweeks and is decreased or absent in the adult and
aging brain [49]. The inclusion of GABAAα3 in the receptor is reportedly
the reason for the slow kinetics during early postnatal development,
and a developmental switch from α3 to α1 is essential for a faster
kinetics [44]. This developmental switch in GABAA subunits occurs in
rats [41,42,43], cats [40], and macaque monkeys [55]. Such apparent
subunit switches have been suggested to underlie the transition from
depolarizing/excitatory to a hyperpolarizing/inhibitory mode of GABA
action during development [56]. Our present data indicate that Sp4
does not play an important role in regulating this neonatal subunit of
GABAA receptors.
The ratio of the different subunits is a more accurate predictor of
GABAA receptor function than the expression of a single subunit [57,
58]. Yu and colleagues [49] have revealed a continuously lowα3 subunit
and a relatively stable and high α1 and α2 subunit expression in the
cortex during normal aging, and suggested that subunit composition
may modulate the binding of GABA and benzodiazepine to the
receptors. The present study documents that the two key GABAA re-
ceptor subunit genes, Gabra1 and Gabra2, are transcriptionally regu-
lated by Sp4 in neurons, indicating that Sp4's control over GABAA
receptor expression is sustained throughout the postnatal life of
the animal.
The fact that Sp4 plays an important role in regulating mediators of
inhibitory transmission (GABAA receptors; the present study) is signiﬁ-
cant, as we have found that it also regulates many excitatory neuro-
transmitter receptor subunit genes, such as Grin1, Grin2a, and Grin2b
of NMDA receptors [2] and Gria2 of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors [3]. Thus, Sp4 is in an ideal
position to regulate the balance between excitation and inhibition to
achieve a homeostatic state of neuronal functioning. Normal neuronal
functioning is dependent on a proper balance between excitation and
inhibition, both at the single cell and neuronal network levels. Neuronal
ﬁring rate is thought to be maintained around a homeostatic set point,
and the maintenance of that stability is dependent on a number of fac-
tors, including synaptic scaling and the balancing of excitation and inhi-
bition [reviewed in 59]. To date, the mechanism underlying such a
homeostatic balance has not been fully elucidated. We propose that
one suchmechanism is via transcriptional regulation, and that Sp4 is ca-
pable of regulatingmediators of both excitatory glutamatergic [2,3] and
inhibitory GABAergic [present study] neurotransmission. In fact, we
have shown that over-expressing Sp4 up-regulates the mRNA and pro-
tein levels of both glutamatergic receptors [2,3] and GABAergic recep-
tors (the present study), and knocking down Sp4 down-regulates
both. Transcriptional regulation is a viable mechanism that allows foran exquisite orchestration of the delicate balance between excitation
and inhibition.
In addition to regulating mediators of neuronal activity, Sp4 also
transcriptionally regulatesmediators of energy generation (cytochrome
c oxidase or COX) as well as energy consumption (Na+/K+-ATPase) in
neurons [4,5]. COX is the terminal enzyme of themitochondrial electron
transport chain critical in generating ATP, and it has proven to be a sen-
sitive and reliable indicator of neuronal activity [1]. Its 13 subunits are
derived either from the mitochondrial genome or the nuclear DNA
across 9 different chromosomes, and we found that Sp4 regulates all
13 subunits from the two genomes [5]. Na+/K+-ATPase is a plasma
membrane protein that maintains the ionic imbalance across the mem-
brane by actively extruding Na+ in exchange for the inﬂux of K+ [60].
It is a major energy consumer in neurons because of the constant need
for membrane repolarization after depolarizing activities, and its distri-
bution is highly correlated with that of COX, a key energy generator [1].
Thus, Sp4 is a master regulator that tightly couples energy metabolism
(both generation and consumption) with neuronal activity (both exci-
tation and inhibition) at the transcriptional level. This ensures that the
energy requirement of neuronal activity is met with an adequate pro-
duction of energy. The present study also highlights Sp4's role in medi-
ating a homeostatic balance between excitation and inhibition in the
nervous system.
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